Cargando…

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019

OBJECTIVES: To detail the greatest areas of unmet scientific and clinical needs in rheumatology. METHODS: The 21st annual international Advances in Targeted Therapies meeting brought together more than 100 leading basic scientists and clinical researchers in rheumatology, immunology, epidemiology, m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Winthrop, Kevin L, Weinblatt, Michael E, Bathon, Joan, Burmester, Gerd R, Mease, Philip J, Crofford, Leslie, Bykerk, Vivian, Dougados, Maxime, Rosenbaum, James Todd, Mariette, Xavier, Sieper, Joachim, Melchers, Fritz, Cronstein, Bruce N, Breedveld, Ferry C, Kalden, Joachim, Smolen, Josef S, Furst, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Viewpoint
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937409/ https://www.ncbi.nlm.nih.gov/pubmed/31662322 http://dx.doi.org/10.1136/annrheumdis-2019-216151

Ejemplares similares

Advances in rheumatology: new targeted therapeutics
por: Tak, Paul P, et al.
Publicado: (2011)

The changing landscape of biosimilars in rheumatology
por: Dörner, Thomas, et al.
Publicado: (2016)

Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care
por: Poddubnyy, Denis, et al.
Publicado: (2018)

Obstetric rheumatology training is an unmet educational need within the rheumatology community
por: Thorne, Iona, et al.
Publicado: (2020)

Celebrating the global impact of rheumatology research: preface to the Viewpoint Article—‘What are the hot topics in Japanese rheumatology?—Go above and beyond’ by Yoshiya Tanaka, Japan
por: Burmester, Gerd R
Publicado: (2023)

Rheumatology 4.0: big data, wearables and diagnosis by computer
por: Burmester, Gerd R
Publicado: (2018)

Digital crowdsourcing: unleashing its power in rheumatology
por: Krusche, Martin, et al.
Publicado: (2020)

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status
por: van der Bijl, Arie E., et al.
Publicado: (2008)

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search
por: Schoels, Monika, et al.
Publicado: (2010)

Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study
por: Smolen, Josef S, et al.
Publicado: (2019)

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
por: Sieper, Joachim, et al.
Publicado: (2013)

P34 The value of combined ophthalmology and rheumatology review- an unmet need
por: Moorthy, Arumugam, et al.
Publicado: (2021)

Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials
por: Sieper, Joachim, et al.
Publicado: (2014)

Perspectives and limitations of gene expression profiling in rheumatology: new molecular strategies
por: Häupl, Thomas, et al.
Publicado: (2004)

Treating rheumatoid arthritis to target: recommendations of an international task force
por: Smolen, Josef S, et al.
Publicado: (2010)

Rheumatology and COVID-19 at 1 year: facing the unknowns
por: Calabrese, Leonard, et al.
Publicado: (2021)

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update
por: Stoffer, Michaela A, et al.
Publicado: (2016)

COVID-19 pandemic management and the rheumatology patient
por: Varley, Cara D., et al.
Publicado: (2021)

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
por: Emery, P, et al.
Publicado: (2017)

Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study
por: Emery, Paul, et al.
Publicado: (2019)

Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab
por: Rubbert-Roth, Andrea, et al.
Publicado: (2022)

Anti-TNF therapy: what have we learned in 12 years?
por: Kalden, Joachim R
Publicado: (2011)

Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases
por: Kalden, Joachim R
Publicado: (2002)

Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis
por: López-Medina, Clementina, et al.
Publicado: (2019)

Unmet need for patient involvement in rheumatology registries and observational studies: a mixed methods study
por: Studenic, Paul, et al.
Publicado: (2022)

Era of biosimilars in rheumatology: reshaping the healthcare environment
por: Smolen, Josef S, et al.
Publicado: (2019)

Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis
por: Sieper, Joachim, et al.
Publicado: (2011)

An assessment of the current treatment landscape for rheumatology patients in Qatar: Recognising unmet needs and moving towards solutions
por: Emadi, Samar Al, et al.
Publicado: (2017)

Developments in the scientific and clinical understanding of the spondyloarthritides
por: Sieper, Joachim
Publicado: (2009)

Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis
por: Mease, Philip, et al.
Publicado: (2015)

The Evolving Role of the Rheumatology Practitioner in the Care of Immunocompromised Patients in the COVID‐19 Era
por: Calabrese, Leonard H., et al.
Publicado: (2022)

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study
por: Smolen, Josef S, et al.
Publicado: (2020)

Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years
por: Baraliakos, Xenofon, et al.
Publicado: (2013)

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period
por: Emery, Paul, et al.
Publicado: (2015)

Association of hemoglobin levels with radiographic progression in patients with rheumatoid arthritis: an analysis from the BRASS registry
por: Shadick, Nancy, et al.
Publicado: (2023)

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement
por: Schoels, Monika M, et al.
Publicado: (2013)

Management of rheumatic complications of ICI therapy: a rheumatology viewpoint
por: Leipe, Jan, et al.
Publicado: (2019)

Correction: Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
por: Baraliakos, Xenofon, et al.
Publicado: (2005)

Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial
por: Strand, Vibeke, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_bt4q1gbrnj02fk488tr07qk179